Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MASIMO CORPORATION

(MASI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

GUIDANCE: (MASI) MASIMO Expects Fiscal Year 2021 EPS $3.85

07/27/2021 | 04:14pm EDT


© MT Newswires 2021
All news about MASIMO CORPORATION
09/13MASIMO : SuperSensor Technology Gets CE Mark in Europe
MT
09/13MASIMO : Launches Single-patient-use rainbow® SuperSensor™
BU
09/13Masimo Launches Single-Patient-Use Rainbow SuperSensor
CI
09/08MASIMO : to Present in Morgan Stanley 19th Annual Global Healthcare Conference
BU
09/06MASIMO : New Study Investigates the Ability of Masimo ORi™ to Provide Early Warning ..
BU
09/06New Study Investigates the Ability of Masimo Ori™ to Provide Early Warning of Hypoxemia..
CI
08/31MASIMO : Partners with Penington Institute to Raise Awareness of Harm from Prescription Op..
BU
08/30MASIMO : SafetyNet Alert™ Launches in Western Europe
BU
08/30Masimo SafetyNet Alert™ Launches in Western Europe
CI
08/26MASIMO : Society for the Advancement of Patient Blood Management (SABM) Publication Recomm..
BU
More news
Analyst Recommendations on MASIMO CORPORATION
More recommendations
Financials (USD)
Sales 2021 1 217 M - -
Net income 2021 222 M - -
Net cash 2021 783 M - -
P/E ratio 2021 71,3x
Yield 2021 -
Capitalization 15 037 M 15 037 M -
EV / Sales 2021 11,7x
EV / Sales 2022 10,4x
Nbr of Employees 2 000
Free-Float 70,6%
Chart MASIMO CORPORATION
Duration : Period :
Masimo Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MASIMO CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 273,11 $
Average target price 281,50 $
Spread / Average Target 3,07%
EPS Revisions
Managers and Directors
Joe E. Kiani Chairman & Chief Executive Officer
Micah Young Chief Financial Officer & Executive Vice President
Yongsam Lee Chief Information Officer & Executive VP
Anand Sampath Executive VP-Operations & Clinical Research
Jon Curtis Coleman President-Worldwide Sales & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
MASIMO CORPORATION1.76%15 037
NOVOCURE LIMITED-26.49%13 154
GETINGE AB88.60%11 356
PENUMBRA, INC.58.67%10 158
ASAHI INTECC CO., LTD.-12.75%8 131
SHOCKWAVE MEDICAL, INC.106.22%7 518